Grifols (NASDAQ:GRFS) Shares Gap Up - What's Next?

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $9.00, but opened at $9.44. Grifols shares last traded at $9.62, with a volume of 483,885 shares.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GRFS shares. Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. raised their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a report on Tuesday, June 17th.

Grifols Stock Performance

The company has a market capitalization of $6.70 billion, a price-to-earnings ratio of 8.32, a price-to-earnings-growth ratio of 0.35 and a beta of 0.55. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.97 and a current ratio of 2.60. The company's fifty day simple moving average is $8.47 and its two-hundred day simple moving average is $7.76.

Institutional Investors Weigh In On Grifols

Institutional investors have recently modified their holdings of the business. Versant Capital Management Inc bought a new stake in shares of Grifols during the 1st quarter valued at about $28,000. Tower Research Capital LLC TRC grew its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after buying an additional 6,335 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Grifols during the 4th quarter valued at about $75,000. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Grifols during the 4th quarter valued at about $77,000. Finally, Ballentine Partners LLC bought a new stake in shares of Grifols during the 1st quarter valued at about $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.